Yuhan Wang

Yuhan Wang

Auto-generated profile, based on publicly available information

Yuhan Wang

Department of Psychiatry, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 May 2023 in Journal of Diabetes
Verified
Journal Article
Open access
JWJincheng Wang
Jincheng Wang
YWYuhan Wang
Yuhan Wang
YWYueheng Wang
Yueheng Wang
YLYu Li
Yu Li
JZJiamei Zhang
Jiamei Zhang
HLHongzhou Liu
Hongzhou Liu
Background: Changes in vascular function are closely associated with the development of cardiovascular disease (CVD). Pulse wave velocity (PWV) is a potential indicator of vascular dysfunction; it allows noninvasive assessment of arterial stiffness. Currently, evidence for the effects of different classes of antidiabetic drugs on arterial stiffness remains limited. In this study, a network meta‐analysis (NMA) was performed to explore the associations between changes in arterial stiffness and first‐line antidiabetic drugs by evaluating PWV in patients with different metabolic abnormalities.Methods: We systematically searched several electronic databases for randomized controlled trials (RCTs) published from inception until 25 August 2022, without language restrictions. The primary outcome was the change in PWV (ΔPWV) in all included studies; subgroup analysis was performed for patients with abnormal glucose metabolism, including prediabetes and diabetes mellitus. NMA was performed to calculate the mean differences (MDs) with 95% confidence intervals (CIs) as effect sizes to evaluate the ΔPWV.Results: Among the 2257 candidate articles identified in the initial search, 18 RCTs were eventually included in the analysis. In all studies, two classes of new antidiabetic drugs, glucagon‐like peptide‐1 receptor (GLP‐1R) agonists and sSodium‐glucose co‐transporter 2 (SGLT‐2) inhibitors, improved arterial stiffness by decreasing PWV compared with placebo (MD = −1.11, 95% CI: −1.94 to 0.28) and (MD = −0.76, 95% CI: −1.45 to −0.08). A conventional antidiabetic drug, metformin, also showed similar efficacy compared with placebo (MD = −0.73, 95% CI: −1.33 to −0.12). Finally, in subgroup studies of patients with abnormal glucose metabolism diseases, GLP‐1R agonists (MD = −1.06, 95% CI: −2.05 to −0.10) significantly decreased PWV compared with placebo.Conclusion: Three classes of antidiabetic drugs—GLP‐1R agonists, SGLT‐2 inhibitors, and metformin—have the potential to improve arterial stiffness. Among the six classes of antidiabetic drugs analyzed, GLP‐1R agonists constitute the only class of drugs that improves arterial stiffness in patients with abnormal glucose metabolism diseases.

2 June 2023 in Clinical Psychopharmacology and Neuroscience
Verified
Journal Article
Open access
PDF file
YTYongjun Tan
Yongjun Tan
LZLi Zhou
Li Zhou
KGKaiqi Gu
Kaiqi Gu
CXCaihong Xie
Caihong Xie
YWYuhan Wang
Yuhan Wang
Qin YangQin Yang
Qin Yang
Yongjun Tan, Li Zhou, Kaiqi Gu, Caihong Xie, Yuhan Wang, Lijun Cha, Youlin Wu, Jiani Wang, Xiaosong Song, Xia Chen, Hua Hu, Qin Yang. Clin Psychopharmacol Neurosci 2023;21:617-33. https://doi.org/10.9758/cpn.22.1040

25 February 2024 in Journal of Affective Disorders
Verified
Journal Article
Closed access
YWYuhan Wang
Yuhan Wang
JHJie Huang
Jie Huang
HZHanhan Zheng
Hanhan Zheng
LTLi Tao
Li Tao
KGKaiqi Gu
Kaiqi Gu
HHHua Hu
Hua Hu